Table 1.
Patent filed for xanthine derivatives in last twenty years (2002–2020).
| S. No. | Patent application number | Year of filing | Applicant name | Patent office | Compound | Category |
|---|---|---|---|---|---|---|
| 1 | AU 200521 958-B2 [6] | 2005 | Boehringer Ingelheim International GmbH | Australian |
|
DPP-IV inhibitor |
|
| ||||||
| 2 | CA 02873524 [7] | 2007 | Boehringer Ingelheim International GmbH | Canadian | 1-[(4-methyl-quinazolin-2-yl)methyl]-3-7-(2-butyn-1-yl)-8-(3-(R)-aminopiperidin-1-yl) xanthine | DPP-IV inhibitor |
|
| ||||||
| 3 | EP 2058311A2 [8] | 2003 | Boehringer Ingelheim International GmbH and Co. | European patent office |
|
DPP-IV inhibitor |
|
| ||||||
| 4 | DE 6020050 00 986T2 [9] | 2005 | Loreal Paris | Deutsches patent under Markenamt | — | Obesity |
|
| ||||||
| 5 | EP 1368349 B1 [10] | 2002 | Boehringer Ingelheim International GmbH and Co. | Europian |
|
DPP-IV |
|
| ||||||
| 6 | EP 1515972 B1 [11] | 2003 | F.Hoffman-La Roche AG 4070 Basel (CH) | Europian |
|
Type-II diabetes |
|
| ||||||
| 7 | EP 1599477 B1 [12] | 2004 | F.Hoffman-La Roche AG 4070 Basel (CH) | Europian |
|
PEPCK inhibitors |
|
| ||||||
| 8 | EP 1689748 B1 [13] | 2004 | Boehringer Ingelheim International GmbH | Europian |
|
Diabetes |
|
| ||||||
| 9 | ES 2401128 T3 [14] | 2006 | GlaxoSmithKline LLC | Spain |
|
Agonist of HM74 A |
|
| ||||||
| 10 | US 7696212 B2 [15] | 2010 | Boehringer Ingelheim International GmbH and Co. KG | United States |
|
DPP-IV inhibitor |
|
| ||||||
| 11 | US 7838529 B2 [16] | 2010 | Boehringer Ingelheim International GmbH, Ingelheimam Rhein (DE) | United States |
|
Type-2 diabetes mellitus, antiobesity. |
|
| ||||||
| 12 | US 7879864 B2 [17] | 2011 | Sanofi-Aventis Deutschland GmbH, Frankfurt am main (DE) | United States |
|
DPP-IV inhibitor |
|
| ||||||
| 13 | US 9221821 B2 [18] | 2015 | Forest Laboratories Holdings Limited, Hamilton (BM) | United States |
|
- |
|
| ||||||
| 14 | US 10202383 B2 [19] | 2019 | Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE) | United States |
|
DPP-IV |
|
| ||||||
| 15 | US 10214530 B2 [20] | 2019 | Max-Delbruck-Centrum Fur Molekulare Medizin, Berlin (De), Forschungs-Verbund-Berlin-E. V., Berlin (De) | United States |
|
Serotonin based disease |
|
| ||||||
| 16 | US 201111 8464 [21] | 2009 | Ing-Jun Chen Linya District (TW) | United States |
|
Anticancer |